瑞舒伐他汀对冠心病患者心功能、血脂水平及血液流变学指标的影响研究

Effect of rosuvastatin on cardiac function,blood lipid levels and blood rheology in patients with coronary heart disease

目的探讨瑞舒伐他汀对冠心病患者心功能、血脂水平及血液流变学指标的影响。方法选取2012年3月—2015年7月赣州市中医院收治的确诊为冠心病患者81例,按照随机数字表法分为对照组40例与治疗组41例。对照组给予常规治疗,治疗组在对照组基础上给予瑞舒伐他汀治疗。比较两组患者治疗前及治疗后血脂指标〔总胆固醇(TC)、三酰甘油(TG)、低密度脂蛋白胆固醇(LDL-C)〕、心功能指标〔左心室舒张末期容积(LVEDV)、左心室收缩末期容积(LVESV)、左室射血分数(LVEF)〕、血液流变学指标〔纤维蛋白原(Fib)、血浆黏度、血黏度(低切、高切)〕及不良反应发生情况。结果治疗前两组患者TC、TG、LDL-C水平比较,差异无统计学意义(P>0.05);治疗后治疗组患者TC、TG、LDL-C水平低于对照组,差异有统计学意义(P<0.05);治疗后治疗组TC、TG、LDL-C水平低于治疗前,差异有统计学意义(P<0.05)。治疗前两组患者LVESV、LVEDV、LVEF比较,差异无统计学意义(P>0.05);治疗后治疗组患者LVESV、LVEDV低于对照组,LVEF高于对照组,差异有统计学意义(P<0.05)。治疗前两组患者Fib、血浆黏度、血黏度水平比较,差异无统计学意义(P>0.05);治疗后治疗组患者Fib、血浆黏度、血黏度水平低于对照组,差异有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论瑞舒伐他汀治疗冠心病可更好地改善患者心功能、血脂水平及血液流变学指标。

Objective To investigate the impact of rosuvastatin on cardiac function,blood lipid levels and blood rheology in patients with coronary heart disease. Methods From March 2012 to July 2015 in the Hospital of Traditional Chinese Medicine of Ganzhou City 81 patients diagnosed with coronary heart disease were selected,according to the random number table they were divided into the control group( 41 cases) and the treatment group( 40 cases). The control group received conventional treatment,the treatment group was given rosuvastatin treatment on the basis of the control group. Before and after treatment serum lipids 〔total cholesterol( TC),triglyceride( TG),low density lipoprotein cholesterin( LDL- C) 〕,cardiac function〔left ventricular end- diastolic volume( LVEDV),left ventricular end- systolic volume( LVESV),left ventricular ejection fraction( LVEF) 〕,blood rheology 〔fibrinogen( Fib),plasma viscosity,blood viscosity( low- cut,high- cut) 〕and occurrence of adverse reactions between the two groups were compared. Results Before treatment TC,TG,LDL- C levels between the two groups showed no significant differences( P > 0. 05); after treatment,TC,TG,LDL- C levels of treatment group were lower than the control group and before treatment( P < 0. 05). Before treatment LVESV,LVEDV,LVEF between the two groups showed no significant differences( P > 0. 05); after treatment LVESV,LVEDV of the treatment group were lower than the control group,LVEF was higher than the control group( P < 0. 05). Before treatment Fib,plasma viscosity,blood viscosity between the two groups showed no significant differences( P > 0. 05); after treatment Fib,plasma viscosity,blood viscosity levels of the treatment group were lower than the control group( P < 0. 05). Adverse reactions rate between the two groups showed no significant differences( P > 0. 05). Conclusion Rosuvastatin can improving cardiac function,blood lipid levels and blood rheology of patients in the treatment of coronary heart disease.